B8063

BML-210

≥98% (HPLC), powder

• Synonym(s): N1-(2-aminophenyl)-N8-phenyl-octanediamide
• Empirical Formula (Hill Notation): C₂₀H₂₅N₃O₂
• CAS Number: 537034-17-6
• Molecular Weight: 339.43
• NACRES: NA.77
• PubChem Substance ID: 329773304
• UNSPSC Code: 12352200
• MDL number: MFCD08062139
• eCl@ss: 32150313
• Assay: ≥98% (HPLC)
• Form: powder

Properties

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to very faintly yellow
• solubility: DMSO: >20 mg/mL
• storage temp.: 2-8°C
• SMILES string: Nc1ccccc1NC(=O)CCCCCCC(=O)Nc2ccccc2
• InChI: 1S/C20H25N3O2/c21-17-12-8-9-13-18(17)23-20(25)15-7-2-1-6-14-19(24)22-16-10-4-3-5-11-16/h3-5,8-13H,1-2,6-7,14-15,21H2,(H,22,24)(H,23,25)
• InChI key: RFLHBLWLFUFFDZ-UHFFFAOYSA-N

Description

Biochem/physiol Actions

BML-210 is a histone deacetylase inhibitor. Treatment of A549 cells with BML-210 results in a dose-dependent increase in acetylated histone levels (EC50 = 36 μM). In HeLa extracts, the IC50 for inhibition of HDAC activity is 80 μM.

BML-210 is an HDAC inhibitor.

BML-210 is a synthetic benzamide and is a potential tumor inhibitor. It is used as a therapeutic agent to treat promyelocytic leukemia. In human leukemia cell lines (NB4, HL-60, THP-1, and K562), BML-210 modulates histone deacetylase and promotes apoptosis. BML-210 favors frataxin expression in neurodegenerative disease Friedreich′s ataxia (FRDA). It interacts with myocyte enhancer factor-2 (MEF2) via hydrogen-bonding and prevents histone deacetylase 4 (HDAC4) binding.

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Safety Information

• Hazard Codes: H413
• Precautionary Statements: P273 - P501
• Hazard Classifications: Aquatic Chronic 4
• Storage Class: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable